
John D. Lambris, Ph.D.
@lambrisjd
Dr. Ralph & Sallie Weaver Professor of Res. Medicine/ #University of Pennsylvania, Founder of #Amyndas, Inventor of #compstatins. Founder of #Aegean Conferences
ID: 937852951439314944
http://www.lambris.com 05-12-2017 01:15:42
275 Tweet
536 Followers
77 Following






Add a placeholder on your calendars and make sure you join us in Greece for the 20th Aegean Conferences on Innate Immunity! This milestone meeting will take place in Sissi, Crete from June 15-20, 2025. We will be discussing all the latest developments in various aspects of innate



Amid the dust settling from the 'explosion' of clinical approvals, here's our spotlight w/John D. Lambris, Ph.D. on the first ever therapy for patients with geographic atrophy, the #compstatin based #C3 targeted drug #Syfovre #pegcetacoplan Now out in Trends in Pharmacological Sciences sciencedirect.com/science/articl…



Speakers Posted: 17th Int'l Conference on #ComplementTherapeutics held in #Sissi, #Crete, #Greece from May 10-15, 2025 KALIMERA KRITI organized by John D. Lambris, Ph.D. Dimitris Mastellos Lubka Roumenina aegeanconferences.org/src/App/confer…





Our News & Views article with Dimitris Mastellos discussing two recent Nature studies that report #granzymeK-mediated #complement activation in pathological contexts of CD8+ #Tcell-driven tissue #inflammation is now out in Nature Immunology nature.com/articles/s4159…


Program Updated: 17th Int'l Conference on #Complement #Therapeutics held at the #KalimeraKriti Conference Center from May 10-15 in #Sissi #Crete #Greece aegeanconferences.org/src/App/sessio… Dimitris Mastellos Lubka Roumenina John D. Lambris, Ph.D.


Pleased to share our newly published paper entitled: "Clinical C3 Inhibition With AMY-101 Reveals Novel Insights Into IL-8–Driven Inflammation in COVID-19" onlinelibrary.wiley.com/doi/10.1111/im… This work, which was done a few years back, investigated the effects of AMY-101 in treating severe

Syfovre, the PEGylated version of a 2nd-generation compstatin-based C3 therapeutic (Cp05) discovered in my lab at the University of Pennsylvania (pubmed.ncbi.nlm.nih.gov/16854067/) shows a consistent safety profile over 36 months of treatment, with increasing efficacy in reducing GA lesion
